New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
06:36 EDTAERIAerie Pharmaceuticals reports positive results from AR-13324 study
Aerie Pharmaceuticals announced the results of preclinical in vivo research demonstrating the ability of AR-13324 to reduce episcleral venous pressure, or EVP, in the eye. AR-13324 previously has been shown to lower intraocular pressure, or IOP, by increasing fluid outflow through the trabecular pathway, the eye's primary drain, and by reducing the production of fluid in the eye. The present study affirmed the hypothesis that AR-13324 also can lower IOP through a third mechanism of action, the reduction of EVP. This may represent a breakthrough in the lowering of IOP in patients with glaucoma and ocular hypertension.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
10:00 EDTAERIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
March 24, 2015
16:06 EDTAERIAerie Pharmaceuticals initiated with a Buy at Brean Capital
Subscribe for More Information
06:02 EDTAERIAerie Pharmaceuticals completes enrollment for Phase 3 trial of Rhopressa
Aerie Pharmaceuticals announced the completion of enrollment in the Company’s second Phase 3 registration trial of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure,or IOP, in patients with glaucoma or ocular hypertension. Rocket 2 will measure efficacy over three months, as well as safety over one year. The primary efficacy endpoint of the trial is to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use